logo
Plus   Neg
Share
Email

Johnson & Johnson Ordered To Pay $750 Mln In New Jersey Baby Powder Case

A New Jersey jury has ordered Johnson & Johnson (JNJ) to pay $750 million in punitive damages to four cancer victims who charged that the company's Johnson's Baby Powder contained cancer-causing asbestos.

The jury agreed that J&J had acted "maliciously or in wanton disregard" of the safety risks of the four plaintiffs.

"This case is really about the fact that J&J structured their last 50 years of conduct around concealing that there were, and have always been, asbestos fibers in their baby powder," said trial lawyer Chris Panatier of Dallas-based Simon Greenstone Panatier. "They designed test methods that they knew lacked the sensitivity to detect the asbestos that was present and then on the occasions when asbestos was found, took steps to make excuses, blame non-existent contamination, delete and alter test results. The jury saw all of that."

In September, a separate jury found Johnson & Johnson liable in the lawsuit by plaintiffs Douglas Barden, David Etheridge, D'Angela McNeill and Will Ronning and awarded $37.3 million in actual damages.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT